NO20054141L - 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse - Google Patents
2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelseInfo
- Publication number
- NO20054141L NO20054141L NO20054141A NO20054141A NO20054141L NO 20054141 L NO20054141 L NO 20054141L NO 20054141 A NO20054141 A NO 20054141A NO 20054141 A NO20054141 A NO 20054141A NO 20054141 L NO20054141 L NO 20054141L
- Authority
- NO
- Norway
- Prior art keywords
- ring
- group
- medicament
- optionally substituted
- alkyl group
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 3
- 150000008318 pyrimidones Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 2
- 238000004519 manufacturing process Methods 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 abstract 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 abstract 1
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 abstract 1
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 abstract 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical group C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical group C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical group C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20030290571 EP1454908B1 (en) | 2003-03-07 | 2003-03-07 | Substituted pyridinyl-2-(diaza-bicyclo-alkyl)-pyrimidinone derivatives |
| EP03290570A EP1454910A1 (en) | 2003-03-07 | 2003-03-07 | Substituted pyrimidinyl-2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
| PCT/EP2004/003050 WO2004078759A1 (en) | 2003-03-07 | 2004-03-05 | Substituted 2-(diaza-bicyclo-alkyl)-pyrimidone derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20054141D0 NO20054141D0 (no) | 2005-09-06 |
| NO20054141L true NO20054141L (no) | 2005-12-07 |
Family
ID=32963795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20054141A NO20054141L (no) | 2003-03-07 | 2005-09-06 | 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US7211581B2 (enExample) |
| EP (1) | EP1603910B1 (enExample) |
| JP (1) | JP4778890B2 (enExample) |
| KR (1) | KR101072159B1 (enExample) |
| AR (1) | AR043486A1 (enExample) |
| AT (1) | ATE440844T1 (enExample) |
| AU (1) | AU2004218249B2 (enExample) |
| BR (1) | BRPI0408186A (enExample) |
| CA (1) | CA2516934C (enExample) |
| CY (1) | CY1111132T1 (enExample) |
| DE (1) | DE602004022784D1 (enExample) |
| DK (1) | DK1603910T3 (enExample) |
| EA (1) | EA008595B1 (enExample) |
| ES (1) | ES2332132T3 (enExample) |
| IL (1) | IL170468A (enExample) |
| MX (1) | MXPA05009575A (enExample) |
| NO (1) | NO20054141L (enExample) |
| NZ (1) | NZ542136A (enExample) |
| PL (1) | PL1603910T3 (enExample) |
| PT (1) | PT1603910E (enExample) |
| SI (1) | SI1603910T1 (enExample) |
| WO (1) | WO2004078759A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200813015A (en) | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| EP1992620A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases |
| EP1992625A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Arylamide pyrimidone compounds |
| EP1992624A1 (en) | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide pyrimidone compounds |
| EP1992621A1 (en) * | 2007-05-16 | 2008-11-19 | Sanofi-Aventis | Heteroarylamide-substituted pyrimidone derivatives for the treatment of neurodegenerative diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994460A (en) * | 1989-06-01 | 1991-02-19 | Bristol-Myers Squibb Co. | Agents for treatment of brain ischemia |
| US5883254A (en) * | 1996-11-08 | 1999-03-16 | Hoffmann-La Roche Inc. | Process for making pyrimidine derivatives |
| EP1136483A1 (en) * | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
| AU2001262150A1 (en) * | 2000-03-23 | 2001-10-03 | Mitsubishi Pharma Corporation | 2-(nitrogen-heterocyclic)pyrimidone derivatives |
| ES2250883T3 (es) * | 2002-02-28 | 2006-04-16 | Sanofi-Aventis | Derivados de 2-piridinil y 2-pirimidinil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona sustituidos con heteroarilo. |
-
2004
- 2004-03-05 AR ARP040100695A patent/AR043486A1/es not_active Application Discontinuation
- 2004-03-05 DK DK04717644T patent/DK1603910T3/da active
- 2004-03-05 ES ES04717644T patent/ES2332132T3/es not_active Expired - Lifetime
- 2004-03-05 DE DE602004022784T patent/DE602004022784D1/de not_active Expired - Lifetime
- 2004-03-05 WO PCT/EP2004/003050 patent/WO2004078759A1/en not_active Ceased
- 2004-03-05 PT PT04717644T patent/PT1603910E/pt unknown
- 2004-03-05 MX MXPA05009575A patent/MXPA05009575A/es active IP Right Grant
- 2004-03-05 NZ NZ542136A patent/NZ542136A/en not_active IP Right Cessation
- 2004-03-05 CA CA2516934A patent/CA2516934C/en not_active Expired - Fee Related
- 2004-03-05 EA EA200501243A patent/EA008595B1/ru not_active IP Right Cessation
- 2004-03-05 JP JP2006504812A patent/JP4778890B2/ja not_active Expired - Fee Related
- 2004-03-05 AU AU2004218249A patent/AU2004218249B2/en not_active Ceased
- 2004-03-05 EP EP04717644A patent/EP1603910B1/en not_active Expired - Lifetime
- 2004-03-05 SI SI200431263T patent/SI1603910T1/sl unknown
- 2004-03-05 AT AT04717644T patent/ATE440844T1/de active
- 2004-03-05 BR BRPI0408186-2A patent/BRPI0408186A/pt not_active IP Right Cessation
- 2004-03-05 PL PL04717644T patent/PL1603910T3/pl unknown
-
2005
- 2005-08-23 IL IL170468A patent/IL170468A/en not_active IP Right Cessation
- 2005-09-06 US US11/219,923 patent/US7211581B2/en not_active Expired - Fee Related
- 2005-09-06 NO NO20054141A patent/NO20054141L/no not_active Application Discontinuation
- 2005-09-06 KR KR1020057016636A patent/KR101072159B1/ko not_active Expired - Fee Related
-
2007
- 2007-03-29 US US11/693,345 patent/US7452897B2/en not_active Expired - Fee Related
-
2009
- 2009-10-26 CY CY20091101113T patent/CY1111132T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101072159B1 (ko) | 2011-10-10 |
| NZ542136A (en) | 2008-07-31 |
| EP1603910B1 (en) | 2009-08-26 |
| US20070167455A1 (en) | 2007-07-19 |
| AU2004218249A1 (en) | 2004-09-16 |
| CA2516934A1 (en) | 2004-09-16 |
| MXPA05009575A (es) | 2006-05-19 |
| JP2006519813A (ja) | 2006-08-31 |
| US7452897B2 (en) | 2008-11-18 |
| US20060025417A1 (en) | 2006-02-02 |
| EP1603910A1 (en) | 2005-12-14 |
| NO20054141D0 (no) | 2005-09-06 |
| CY1111132T1 (el) | 2015-06-11 |
| JP4778890B2 (ja) | 2011-09-21 |
| ATE440844T1 (de) | 2009-09-15 |
| KR20050113218A (ko) | 2005-12-01 |
| AR043486A1 (es) | 2005-08-03 |
| BRPI0408186A (pt) | 2006-04-04 |
| PL1603910T3 (pl) | 2010-02-26 |
| ES2332132T3 (es) | 2010-01-27 |
| IL170468A (en) | 2010-12-30 |
| PT1603910E (pt) | 2009-10-30 |
| US7211581B2 (en) | 2007-05-01 |
| WO2004078759A1 (en) | 2004-09-16 |
| CA2516934C (en) | 2011-09-20 |
| SI1603910T1 (sl) | 2009-12-31 |
| DE602004022784D1 (de) | 2009-10-08 |
| DK1603910T3 (da) | 2009-11-23 |
| AU2004218249B2 (en) | 2009-04-30 |
| EA008595B1 (ru) | 2007-06-29 |
| HK1085742A1 (zh) | 2006-09-01 |
| EA200501243A1 (ru) | 2006-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20054140L (no) | Dihydrospiro-[cykloalkyl]-pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse, og mellomproduktforbindelse | |
| Göker et al. | Synthesis and potent antibacterial activity against MRSA of some novel 1, 2-disubstituted-1H-benzimidazole-N-alkylated-5-carboxamidines | |
| Choi et al. | Optimization of vinyl sulfone derivatives as potent nuclear factor erythroid 2-related factor 2 (Nrf2) activators for Parkinson’s disease therapy | |
| NO20054331L (no) | Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| NO20054330L (no) | 8-substituerte-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater | |
| AU2013366898B2 (en) | Halogen-substituted heterocyclic compound | |
| BRPI0417208A (pt) | derivados de 8'-piri(mi)dinil-diidroespiro-[cicloalquilamina]-pirimid o[1,2-ona]pirimidin-6-ona | |
| EP2598480A1 (en) | Cyclopropylamine derivatives useful as lsd1 inhibitors | |
| Giles et al. | Synthesis pharmacological evaluation and docking studies of pyrimidine derivatives | |
| EA024702B1 (ru) | Новые иммуномодуляторные и противовоспалительные соединения | |
| MX2009006947A (es) | Derivados de pirimidona 6-heterociclica 2-sustituida. | |
| NO20092373L (no) | Substituerte heteroarylpyridopyrimidonderivater | |
| Cheng et al. | Synthesis of 5-methyl phenanthridium derivatives: A new class of human DOPA decarboxylase inhibitors | |
| Webber et al. | Substituted 2-iminopiperidines as inhibitors of human nitric oxide synthase isoforms | |
| EA200400936A1 (ru) | ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ 2-ПИРИДИНИЛ- И 2-ПИРИМИДИНИЛ-6,7,8,9-ТЕТРАГИДРОПИРИМИДО[1,2-a]ПИРИМИДИН-4-ОНА | |
| MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
| EA200801134A1 (ru) | Замещенные бициклические пиримидоновые производные | |
| Jiang et al. | Discovery of 3-(4-sulfamoylnaphthyl) pyrazolo [1, 5-a] pyrimidines as potent and selective ALK2 inhibitors | |
| NO20054141L (no) | 2-(diazabicykloalkyl)pyrimidonderivat, anvendelser derav for fremstilling av et medikament, medikament omfattende en slik forbindelse og mellomproduktforbindelse | |
| NO20051901L (no) | Nye antimycobakterielle sammensetninger og pyrrole derivater som antimycobakterielle sammensetninger | |
| BR0308106A (pt) | Derivados de 1-[alquil], 1[(heteroaril)alquil] e 1-[(aril)alquil]-7-(pirimidin-4-il)-imidazo[1,2-a]pirimidin-5- (1h)-ona | |
| EA201070367A1 (ru) | Производное 6-пиримидинилпиримид-4-она | |
| WO2008053863A1 (en) | Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton | |
| PT1315730E (pt) | Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona | |
| CZ327494A3 (en) | Esters of nicotinic acid and process for preparing thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |